EIF2S1 Antibody

What is EIF2S1 and what is its functional significance in cellular processes?

EIF2S1, also known as eIF2-alpha, is a key component of the eukaryotic translation initiation factor 2 complex that functions in the early steps of protein synthesis. It binds GTP and initiator tRNA (Met-tRNAi) and transfers Met-tRNAi to the 40S ribosomal subunit . This complex then binds to mRNA to form a 43S pre-initiation complex (43S PIC) . Beyond its role in translation, EIF2S1 serves as a critical component of the integrated stress response (ISR), where its phosphorylation at serine 51 converts it into a global protein synthesis inhibitor while simultaneously initiating the preferential translation of ISR-specific mRNAs . Additionally, EIF2S1 functions as an activator of mitophagy in response to mitochondrial damage, where phosphorylation by EIF2AK1/HRI promotes its relocalization to the mitochondrial surface, triggering PRKN-independent mitophagy .

What types of EIF2S1 antibodies are available for research applications?

Researchers have access to several types of EIF2S1 antibodies, each with specific characteristics:

When selecting an antibody, researchers should consider the specific application, target species, and whether total EIF2S1 or its phosphorylated form is of interest. The phospho-specific antibody (pSer51) is particularly valuable for studying stress response pathways, while antibodies against total EIF2S1 are essential for normalization and comparative studies .

How should EIF2S1 antibodies be stored and handled to maintain their efficacy?

Proper storage and handling of EIF2S1 antibodies are critical for maintaining their performance. Most EIF2S1 antibodies are provided in a liquid form with PBS buffer containing glycerol (typically 50%) and sodium azide (0.02%) . The recommended storage temperature is -20°C, where they remain stable for approximately one year after shipment . For the 20μl size antibodies that contain 0.1% BSA, aliquoting is generally unnecessary for -20°C storage . When working with these antibodies, minimize freeze-thaw cycles by briefly thawing only the amount needed for experiments and keeping the remainder frozen. Always centrifuge briefly before opening vials to collect all liquid at the bottom of the tube. For long-term storage beyond one year, consider creating small aliquots to avoid repeated freeze-thaw cycles that could degrade antibody performance.

What are the optimal dilution ratios for different applications of EIF2S1 antibodies?

The optimal dilution ratios vary significantly depending on the application and the specific antibody used. Based on the data from antibody suppliers, here are the recommended dilutions:

It is strongly recommended to optimize these dilutions for each experimental system, as factors such as sample type, protein expression level, and detection method can significantly influence the optimal antibody concentration . Start with the manufacturer's recommended dilution range and perform a titration experiment to determine the optimal concentration for your specific application.

How can I validate the specificity of EIF2S1 antibodies in my experimental system?

Validating antibody specificity is crucial for ensuring reliable results. For EIF2S1 antibodies, several approaches are recommended:

• Positive controls: Use cell lines or tissues known to express EIF2S1. For example, A549, HepG2, LNCaP, HeLa, Jurkat, K-562, HEK-293, HSC-T6, and NIH/3T3 cells have been validated for EIF2S1 expression .

• Negative controls: Include samples where EIF2S1 is knocked down using siRNA or shRNA methods. A recent neuroblastoma study used shRNA-mediated EIF2S1 knockdown that can serve as a validation approach .

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight. EIF2S1 has a calculated molecular weight of 36 kDa, which should be consistent with the observed molecular weight in Western blots .

• Phospho-specificity validation: For phospho-specific antibodies (e.g., pSer51), treat samples with phosphatase to confirm that signal disappears, or induce phosphorylation using stress conditions known to activate EIF2S1 kinases.

• Multiple antibody comparison: Use antibodies from different sources or clones targeting different epitopes of EIF2S1 to confirm consistent results.

These validation steps are essential before proceeding with complex experimental setups and will significantly enhance the reliability of research findings involving EIF2S1.

How can EIF2S1 antibodies be used to study the integrated stress response (ISR) pathway?

EIF2S1 phosphorylation at serine 51 is a central event in the integrated stress response (ISR), making phospho-specific antibodies powerful tools for studying this pathway. To effectively investigate the ISR using EIF2S1 antibodies:

• Stress induction protocols: Treat cells with specific stressors that activate different EIF2S1 kinases (EIF2AK1/HRI, EIF2AK2/PKR, EIF2AK3/PERK, and EIF2AK4/GCN2) . Common stressors include thapsigargin (ER stress), sodium arsenite (oxidative stress), tunicamycin (ER stress), or amino acid deprivation (GCN2 activation).

• Time-course experiments: Monitor EIF2S1 phosphorylation over time using anti-EIF2S1 (pSer51) antibodies to understand the dynamics of the ISR activation . Simultaneously track total EIF2S1 levels using antibodies against total protein.

• Downstream target analysis: Combine EIF2S1 phosphorylation detection with analysis of downstream ISR targets such as ATF4 and QRICH1, which are preferentially translated during stress .

• Translational regulation assessment: Pair EIF2S1 antibody data with polysome profiling or ribosome footprinting to correlate phosphorylation status with global and mRNA-specific translation rates.

• Pharmacological modulators: Evaluate the effects of ISR inhibitors (ISRIB) or activators on EIF2S1 phosphorylation status and downstream pathways.

By integrating these approaches, researchers can gain comprehensive insights into how different stressors trigger the ISR and how cells adapt through translational reprogramming mediated by EIF2S1 phosphorylation.

What is the role of EIF2S1 in cancer biology, and how can antibodies help investigate this connection?

EIF2S1 plays significant roles in cancer biology, with recent research highlighting its importance in tumor development and progression. EIF2S1 antibodies are valuable tools for investigating these connections:

• Prognostic marker assessment: Elevated EIF2S1 expression has been correlated with poor prognosis in breast cancer patients . Researchers can use EIF2S1 antibodies in tissue microarrays or immunohistochemistry to evaluate expression levels across patient samples and correlate with clinical outcomes.

• Ferroptosis resistance mechanisms: A recent study demonstrated that EIF2S1 facilitates neuroblastoma progression by protecting tumor cells from ferroptosis through modulation of GPX4 and SLC7A11 expression . Antibodies against both total and phosphorylated EIF2S1 can help monitor these pathways in various cancer types.

• Stress response adaptation: Cancer cells often exist in stressful microenvironments (hypoxia, nutrient deprivation). EIF2S1 phosphorylation at serine 51 has been shown to be a determinant of survival and adaptation in glucose-deficient cells . Using phospho-specific antibodies, researchers can track how cancer cells modulate the ISR to survive these conditions.

• Therapeutic target assessment: As EIF2S1 emerges as a potential therapeutic target, particularly in neuroblastoma , antibodies can be used to monitor changes in expression or phosphorylation status following treatment with experimental compounds.

• Cell fate determination: EIF2S1 phosphorylated at serine 51 acts as a molecular switch determining cell fate decisions in response to stress . This can be investigated in cancer contexts using phospho-specific antibodies combined with cell death assays.

These applications demonstrate how EIF2S1 antibodies serve as critical tools for understanding the complex roles of this protein in cancer biology and potentially identifying new therapeutic strategies.

How can I optimize immunofluorescence protocols to accurately detect subcellular localization of EIF2S1?

Detecting the subcellular localization of EIF2S1, particularly during stress conditions or mitophagy activation, requires carefully optimized immunofluorescence protocols:

• Sample preparation optimization:

  • For adherent cells: Grow cells on coverslips or in chamber slides with appropriate coating (poly-L-lysine or collagen)

  • Fixation method: Test both paraformaldehyde (4%, 10-15 minutes) and methanol (-20°C, 10 minutes) to determine which better preserves EIF2S1 epitopes

  • Permeabilization: Use 0.1-0.5% Triton X-100 in PBS for 5-10 minutes; reduce concentration for phospho-epitopes

• Antibody selection and dilution:

  • For general EIF2S1 detection: Monoclonal antibody 68479-1-Ig at 1:400-1:1600 dilution or polyclonal antibody 11170-1-AP at 1:50-1:500 dilution

  • For phosphorylated EIF2S1: Use phospho-specific antibodies (pSer51)

  • Perform antibody titration to determine optimal concentration for your cell type

• Signal amplification and background reduction:

  • Use signal amplification methods for low-abundance targets

  • Include 5-10% normal serum from the same species as the secondary antibody to reduce background

  • Consider tyramide signal amplification for phospho-EIF2S1 detection

• Co-localization studies:

  • Include markers for specific organelles (e.g., mitochondria, ER, stress granules)

  • For mitophagy studies: Co-stain with mitochondrial markers to detect EIF2S1 translocation to mitochondria

  • Use appropriate fluorophore combinations to avoid spectral overlap

• Controls and validation:

  • Include cells with EIF2S1 knockdown as negative controls

  • For phospho-specific staining, include treatments that increase (stress inducers) or decrease (phosphatase treatment) phosphorylation

  • Validate IF findings with complementary techniques like subcellular fractionation

These optimizations will enable accurate visualization of EIF2S1 localization patterns, particularly during stress conditions or disease states where its subcellular distribution may be altered.

What are common problems encountered when using EIF2S1 antibodies in Western blotting, and how can they be resolved?

Researchers frequently encounter several challenges when using EIF2S1 antibodies in Western blotting applications:

• High background or non-specific bands:

  • Solution: Increase blocking time/concentration (5% BSA or milk), optimize antibody dilution (start with higher dilutions such as 1:10000), and include 0.05-0.1% Tween-20 in washing buffers

  • For phospho-specific antibodies, use 5% BSA instead of milk, as milk contains phosphoproteins

  • Consider using more stringent washing conditions (higher salt concentration or additional washes)

• Weak or no signal for EIF2S1:

  • Solution: Ensure adequate protein loading (20-50 μg of total protein), optimize transfer conditions for 36 kDa proteins, reduce antibody dilution, or increase exposure time

  • For phosphorylated EIF2S1, add phosphatase inhibitors to lysis buffers and maintain samples at 4°C throughout processing

  • Consider using freshly prepared lysates, as phospho-epitopes can be unstable during storage

• Difficulty in detecting phosphorylated EIF2S1:

  • Solution: Include positive controls (cells treated with thapsigargin or other stress inducers known to increase EIF2S1 phosphorylation)

  • Use membrane stripping protocols optimized for phospho-epitopes when reprobing

  • Consider enriching phosphoproteins before Western blotting for low-abundance phospho-EIF2S1

• Inconsistent results between experiments:

  • Solution: Standardize lysate preparation methods, protein quantification techniques, and transfer conditions

  • Use internal loading controls (total EIF2S1 for phospho-EIF2S1 experiments, or housekeeping proteins)

  • Prepare larger batches of antibody dilutions to use across multiple experiments

• Multiple bands appearing at unexpected molecular weights:

  • Solution: Verify antibody specificity with knockout/knockdown controls

  • Test different lysis buffers to ensure complete protein denaturation

  • For suspected degradation products, add additional protease inhibitors to lysis buffer

Implementing these troubleshooting approaches will significantly improve the reliability and reproducibility of Western blotting experiments using EIF2S1 antibodies.

How should I approach contradictory results obtained with different EIF2S1 antibodies?

When faced with contradictory results using different EIF2S1 antibodies, a systematic approach is necessary to resolve discrepancies and ensure data reliability:

• Examine antibody targeting sites:

  • Different antibodies may target distinct epitopes on EIF2S1, some of which might be masked in certain contexts

  • Check manufacturer information for epitope regions and compare across antibodies

  • Phospho-specific antibodies (e.g., pSer51) will naturally give different results from total protein antibodies

• Validate antibody specificity:

  • Perform knockdown/knockout validation for each antibody

  • Compare immunoblot molecular weights with the expected 36 kDa for EIF2S1

  • Test each antibody on the same positive control samples (e.g., HepG2 cells, which are validated for most EIF2S1 antibodies)

• Assess experimental conditions:

  • Different antibodies may perform optimally under different conditions (fixation methods, blocking agents, incubation times)

  • Systematic comparison of protocols for each antibody may reveal condition-dependent discrepancies

  • Phospho-specific antibodies are particularly sensitive to sample handling (phosphatase inhibitors, temperature)

• Consider post-translational modifications:

  • Beyond phosphorylation at Ser51, other modifications may affect antibody recognition

  • Different cell types or treatments may alter the pattern of post-translational modifications

  • Use mass spectrometry to identify potential modifications if resources permit

• Triangulate with orthogonal methods:

  • Employ non-antibody-based detection methods (mass spectrometry, RNA sequencing for transcript levels)

  • Use genetic approaches (overexpression of tagged EIF2S1, CRISPR editing) to validate findings

  • Combine multiple antibodies and techniques to build consensus data

By systematically investigating these factors, researchers can identify the source of contradictions and determine which antibodies provide the most reliable results for their specific experimental context.

How can EIF2S1 antibodies contribute to understanding the role of integrated stress response in neurodegenerative diseases?

The integrated stress response (ISR), mediated through EIF2S1 phosphorylation, has emerged as a critical pathway in neurodegenerative disease pathogenesis. EIF2S1 antibodies offer powerful tools to investigate these connections:

• Biomarker development: Phosphorylated EIF2S1 levels in cerebrospinal fluid or brain tissue can potentially serve as biomarkers for disease progression or treatment response in neurodegenerative conditions. Using phospho-specific antibodies , researchers can develop immunoassays to quantify these changes in patient samples.

• Stress granule dynamics: Many neurodegenerative diseases feature abnormal stress granule formation, which is downstream of EIF2S1 phosphorylation . Antibodies against total and phosphorylated EIF2S1 can help track the relationship between ISR activation and stress granule dynamics in neuronal models of disease.

• Therapeutic target validation: As ISR modulation emerges as a potential therapeutic strategy, EIF2S1 antibodies are essential for confirming target engagement of experimental compounds. They allow researchers to monitor whether interventions successfully modify EIF2S1 phosphorylation status in neuronal cells or animal models.

• Cell-type specific responses: In the complex environment of the brain, different cell types may exhibit varying ISR activation patterns during disease. Using EIF2S1 antibodies in multi-label immunohistochemistry or flow cytometry allows identification of cell-type specific ISR signatures.

• Protein aggregation relationships: Many neurodegenerative diseases feature protein aggregation (amyloid-β, tau, α-synuclein), which may trigger or be influenced by the ISR. Co-immunostaining with EIF2S1 phospho-antibodies and aggregate markers can reveal spatial and temporal relationships between these processes.

These approaches enable researchers to dissect how EIF2S1-mediated stress responses contribute to neurodegeneration and potentially identify new therapeutic interventions targeting this pathway.

What techniques can be used to study the role of EIF2S1 in ferroptosis and anti-cancer strategies?

Recent research has revealed a critical role for EIF2S1 in protecting cancer cells from ferroptosis, particularly in neuroblastoma . Here are methodological approaches using EIF2S1 antibodies to investigate this connection:

• Correlative studies with ferroptosis markers:

  • Use EIF2S1 antibodies alongside GPX4 and SLC7A11 antibodies in Western blotting or IHC to establish correlations between EIF2S1 levels and ferroptosis resistance markers

  • Develop multiplexed immunofluorescence assays to simultaneously detect EIF2S1, phospho-EIF2S1, and ferroptosis pathway components in tissue samples

• Genetic manipulation coupled with antibody detection:

  • Implement shRNA-mediated EIF2S1 knockdown as demonstrated in neuroblastoma research

  • Monitor changes in ferroptosis markers and iron/ROS accumulation following EIF2S1 silencing

  • Use EIF2S1 antibodies to confirm knockdown efficiency and correlate with phenotypic changes

• Pharmacological modulation of EIF2S1 and ferroptosis:

  • Treat cancer cells with ferroptosis inducers (erastin, RSL3) and monitor EIF2S1 expression/phosphorylation status using specific antibodies

  • Combine ISR modulators with ferroptosis inducers to investigate potential synergistic effects

  • Use antibody-based assays to determine mechanism of action for novel compounds

• In vivo modeling and therapeutic development:

  • Develop xenograft models with EIF2S1-modulated cancer cells to study tumor growth in vivo

  • Use antibodies for immunohistochemical analysis of tumor sections to correlate EIF2S1 expression with tumor characteristics

  • Evaluate combination therapies targeting both EIF2S1 and ferroptosis pathways

• Clinical correlation and biomarker development:

  • Apply EIF2S1 antibodies in tissue microarrays to correlate expression with patient outcomes

  • Develop liquid biopsy approaches to detect circulating tumor cells with specific EIF2S1/ferroptosis signatures

  • Stratify patients based on EIF2S1 expression for clinical trials of ferroptosis-inducing therapies

These methodological approaches provide a comprehensive framework for investigating the emerging role of EIF2S1 in ferroptosis resistance and developing potential targeted therapies for cancers like neuroblastoma .

How do different commercially available EIF2S1 antibodies compare in terms of performance and applications?

Selecting the optimal EIF2S1 antibody requires understanding the comparative advantages of different commercial options. The following analysis compares key commercially available antibodies:

Performance considerations:

• Application versatility: The rabbit polyclonal antibody (11170-1-AP) offers the greatest versatility across applications and has the most extensive publication record, making it suitable for researchers who need to employ multiple techniques .

• Specificity considerations: For studying the integrated stress response or stress-induced phosphorylation, the phospho-specific antibody (RM298) provides targeted detection of the activated form . For total protein analysis, the mouse monoclonal antibodies may offer higher specificity but potentially less sensitivity than the polyclonal option.

• Cross-reactivity profile: All antibodies work with human samples, but for studies involving rodent models, the 68479-1-Ig and 11170-1-AP antibodies offer validated cross-reactivity with both mouse and rat .

• Technical applications: For specialized applications like flow cytometry, only the rabbit polyclonal antibody (11170-1-AP) has been validated . Similarly, for immunohistochemistry, the rabbit polyclonal shows superior performance.

This comparative analysis provides researchers with a framework to select the most appropriate EIF2S1 antibody based on their specific experimental requirements, model organism, and technical applications.